Imigran (Sumatriptan)

Sumatriptan works by stimulating 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve fibers. This action produces vasoconstriction of dilated intracranial vessels and blocks the release of inflammatory neuropeptides, interrupting the migraine pain pathway.

The specific dose and frequency are determined by the prescribing clinician based on the patient’s medical history and the severity of the attack. Imigran is supplied as a subcutaneous injection, and the prescriber will decide the appropriate amount for each individual.

Safety data for sumatriptan in pregnancy and lactation are limited. It should only be used when the potential benefit outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified health‑care professional.

To request Imigran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Imigran belongs to the triptan class, which provides faster and more migraine‑specific relief than non‑specific analgesics such as NSAIDs. Compared with oral triptans, the subcutaneous route offers a quicker onset of action, making it useful for patients who need rapid symptom control or who cannot tolerate oral medication.

Imigran should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Imigran is administered as a single subcutaneous injection, typically into the thigh or abdomen. The injection is performed by a health‑care professional or by the patient after proper training, using the pre‑filled syringe supplied with the product.

Serious risks include chest discomfort or tightness, severe hypertension, serotonin syndrome when combined with other serotonergic drugs, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if any of these symptoms occur.

Imigran is contraindicated in patients with uncontrolled hypertension, significant cardiovascular disease, a history of stroke or transient ischemic attack, severe hepatic impairment, and in those taking MAO inhibitors or ergot derivatives. It should also be avoided in individuals with known hypersensitivity to sumatriptan.